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Background: There is evidence suggesting that most thromboembolic complications could be prevented with
adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment
with oral vitamin K antagonists in patients diagnosed with non-valvular atrial fibrillation.
Methods: This observational study examined the clinical records of patients diagnosed with non-valvular atrial
fibrillation who received anticoagulant treatment with oral vitamin K antagonists. Data from clinical records were
used in the study: international normalized ratio, number of monitoring visits, type of anticoagulant, hospital admissions
from complications, and concomitant medication. Drug cost was calculated based on the official Spanish Ministry
of Health price list. Monitoring expenses were included the cost of the medical supplies used in the procedures.
Hospitalization costs were calculated using the Diagnosis Related Group price for each case. Hospital visits costs
were calculated by one of four different scenarios, using either the invoice rates for the regional health care
authority or cost per visit as established by analytical accounting methods.
Results: We collected data from 1,257 patients diagnosed with non-valvular atrial fibrillation who were receiving
oral anticoagulant therapy. Depending on the scheme used, the direct health care costs for these patients ranged
from €423,695 − €1,436,038 per annum. The average cost per patient varied between €392 − €1,341, depending
on the approach used. Patients with international normalized ratio values within the therapeutic range on 25%
of their visits represented an average cost between €441.70 − €1,592. Those within the therapeutic range on 25%–50%
of visits had associated costs of €512.37 − €1,703.91. When international normalized ratio values were within the
therapeutic range on 50% − 75% of the visits, the costs ranged between €400.80− €1,375.74. The average cost
was €305.23 − €1,049.84 when the values were within the therapeutic range for over 75% of visits.
Conclusions: Most direct health care costs associated with the sampled patients arise from the specialist-care
monitoring required for the treatment. Good monitoring is inversely related to direct health care costs.Background
The prevalence of non-valvular atrial fibrillation (NVAF)
increases with age, affecting 0.5% of the population aged
50–59 and almost 10% of those aged 80–89 [1]. The
average age of patients with NVAF is 75, with a greater
prevalence seen among women [1-4]. Findings from the
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the Netherlands report a one-in-four lifetime risk of
developing Atrial Fibrillation (AF) for those over the age
of 40 [2]. Currently, six million Europeans are diagnosed
with AF, and it is estimated that this prevalence will
double over the next 50 years [5]. In the US, some 2.3
million people have NVAF. Estimates based on census
figures and population aging predict that this figure will
rise to 3.3 million by 2020, and to 5.6 million by 2050
[6]. The most common comorbidities seen in NVAF
patients include arterial hypertension, diabetes mellitus,
and previous ischemic heart disease.entral Ltd. This is an open access article distributed under the terms of the
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a five-fold excess risk in patients compared with those
suffering from sinus rhythm. Moreover, the disease causes
10% − 15% of all ischemic strokes, and approximately one
in four strokes in patients aged over 80 [3]. Therefore,
given its associated stroke risk, AF has a clear and sig-
nificant impact on quality of life and mortality, and is a
significant risk factor for stroke recurrence [5].
There is substantial evidence suggesting that most throm-
boembolic complications could be prevented with adequate
pharmacological anticoagulation therapy [6,7]. Long-term
oral anticoagulation therapy (OAT) with vitamin K antago-
nists (VKAs) is prescribed as prophylaxis against strokes
and other embolic events in patients with AF or mechanical
heart valves. VKAs such as warfarin were the cornerstone
of pharmacotherapy for AF in patients with a moderate
to high thromboembolic risk [8]. In clinical trials, antic-
oagulation with adjusted-dose warfarin has been shown
to reduce the risk of ischemic stroke in NVAF patients by
one-half to two-thirds. For this reason, evidence-based
clinical guidelines recommend anticoagulation with war-
farin for patients with NVAF who bear a moderate to high
risk of stroke: 90% of the NVAF population [9]. It has
been shown that improved anticoagulant control can be
achieved through frequent monitoring of the international
normalized ratio (INR), resulting in improved health out-
comes. However, adherence to warfarin is problematic
and strongly associated with poor anticoagulation control
during all phases of therapy. Hence, addressing correct
warfarin dosage and poor adherence issues hold signifi-
cant promise for improving its use as one of the most
commonly prescribed drugs available.
Most NVAF patient interventions and hospital admis-
sions are as a result of the treatment and management
of the disease. Twenty to thirty percent of AF patients
who receive oral VKAs are hospitalized at some point in
their life [10-13]. In the US, NVAF causes approximately
350,000 hospital admissions per year, costing approxi-
mately $3 billion USD [14]. In Europe, direct health care
costs per patient varied between €1,507− €2,328 annually
depending on the country. Of those costs, 40% were
attributable to hospital admissions, 30% to interventions
performed as a result of the disease, and 10% to drug
therapy [5]. Research conducted in the UK that examined
patients receiving warfarin treatment showed that 34% of
the costs paid by the National Health Service (NHS) were
spent on INR monitoring [15].
Despite the significant number of AF cost estimation
studies, only two have focused on Spain [16]. Of these two
studies, one used data from four hospitals where 47% of
the sample had AF. The other patients in the sample were
undergoing OAT but had a different underlying condition
(such as mechanical heart prostheses or rheumatic heart
disease) and hence the results were disaggregated [17].The other study was conducted in five European countries
(including Spain) and estimated AF costs. However, the
patients included in the study were receiving antithrom-
botic therapy rather than OAT [5].
The objective of this study was to estimate the direct
health care costs of patients with NVAF who receive
chronic OAT with VKAs from the perspective of a spe-
cialized anticoagulation unit.
Methods
The study used an observational approach. A retrospective
analysis was performed using the clinical records of patients
who had visited the Hematology Service of the Hospital
Fundación Jiménez Díaz, Madrid, Spain between October
1, 2009 and September 30, 2010. The databases used did
not contain any variable allowing the individual identifica-
tion of patients. According to the legislation in Spain, the
characteristics (observational methodology and retrospect-
ive analysis) of this study do not make it necessary to obtain
authorisation from the hospital Ethics Committee [18].
Patient selection
Patient data was extracted from anonymous clinical records
stored in the hospital databases. Subjects were selected by
members of the research team who worked independently
from the group responsible for statistical analysis. Patients
with diagnosed NVAF and receiving OAT (warfarin sodium
or acenocoumarol) were eligible for inclusion. There was
no gender or age discrimination. To avoid including data
from patients who regularly attend a different hospital, the
team only included data from patients that continuously
visited the hospital for a minimum period of five months
and one day when estimating the patient costs.
Data collection
The data collected included the number of visits made
by each patient, the INR value at the time of each visit, the
OAT dose and regime (measured in average weekly dose
per patient, and type of drug), concomitant medication
(measured in average weekly dose per patient), the devices
required for INR monitoring (a test strip, a pipette, and a
lancet), and hospital admissions caused by complications
resulting from INR values outside the therapeutic range
(TR). Where the patient’s INR was greater than or equal
to five, the result was confirmed by testing either capillary
blood or venous blood.
Data analysis
A previously developed model was used to measure the
period of time when patient INR values fell within the TR
[19]. Visits were classified as either “visits within the TR”
(1.9 < INR < 3.1) or “visits outside the TR” (INR < 1.9 or
INR > 3.1). To calculate the time within the therapeutic
range (TTR), we estimated the number of days when each
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and recorded the INR value of each of these days. The
INR value recorded on a given visit cannot be taken in
isolation. Clinical experience shows that INR readings
fluctuate between visits, and values can fall within the
TR at some times but not at others. Several further
adjustments were made to avoid error. Patients who
had only visited the hospital once were excluded from the
study. Where more than 56 days had elapsed between
any two visits the data were considered not linear and,
therefore, these periods were excluded from the calcu-
lation as previously recommended [19]. INR data collected
in the five days following a known interruption of treat-
ment were considered void.
Health-care resources assessment
The direct health care costs [20] were calculated as the
sum of the following costs: OAT using pharmacological
products, INR measurements, medical visits, rescue drugs
(heparin/vitamin K), and hospitalizations. We consulted
several sources to express the health care resources
consumed in monetary terms. Drug prices (OAT using
pharmacological products and rescue drugs) were obtained
from the Spanish official drug database [21]. The annual




DD P  DTð Þ
Where DD represents daily dose mg/day, P represents
price per mg, and TD represents treatment days.
Two different methods were used to calculate the
cost of hospital visits. The first included the total costs
incurred by the hospital’s hematology service (such as IT
resources, cleaning, electricity, water and other overheads)
in addition to the costs of the healthcare personnel who
intervened during the visit (physicians, nurses, and nurse
assistants). The second method accounted for hospital
visit costs by applying the 2010 regional health service
price list as published in the official region gazette [22].
Four healthcare resource use scenarios were established.
The regional health service price was applied for all visits
in scenario 1. In scenario 2, the regional health service
price was applied for the first and subsequent visits and
different prices were imputed for visits with and without
complications. In the third scenario, the first visit was val-
ued at the regional health service price, and subsequent
visits were valued at the price obtained from the hospital
cost accounting records. Finally, scenario 4 assessed every
hospital visit at the price obtained from the hospital cost
accounting records.
INR measurements included internal assessments of
the health care resources required to perform the test
and, where necessary, the medical equipment needed toconfirm the results obtained (measurements in capillary
or venous blood). Hospital admissions were measured
according to the diagnosis-related group (DRG) price
applied for each particular admission (admissions because
of hemorrhage or thrombosis). All costs were estimated
in current euros for the year 2010.
Results
The final survey size was 1,257 patients ,with a mean age
of 78.41 (standard deviation (SD) = 9.11). Of the patients,
17% (n = 208) had received an NVAF diagnosis for the first
time. The health care resource assessment used data from
those who had regularly visited the hospital for a period
of over five months and one day (n = 944; 75% of the
total population). Table 1 shows a breakdown of both
patient samples.
A total of 17,704 visits were recorded. 69.7% of the
surveyed patients made 11 − 20 visits during the study
period. The average monthly number of visits per patient
was 1.17. Of all visits, 61.8% were classified as having INR
values “within the TR”. In the remaining 38.2% of visits,
the INR value fell outside the TR, and included more
patients with abnormally low INR values (INR < 1.9;
number of visits = 3,203) than those with abnormally
high INR values (INR > 3.1; number of visits = 2,817).
Figure 1 illustrates the number of visits, by INR values,
for all visits made by the 1,257 patients.
52.44% of patients exhibited an INR value below the
TR at some stage during the study period (INR < 1.5),
and 31.14% of patients had an INR reading above the TR
at least once (INR > 4.5). Only 2.54% of the patients had
completely stable INR values throughout the study period.
The prices for anticoagulant treatments and all the unit
costs included in the estimated direct health care costs
appear in Table 2.
The average weekly anticoagulant treatment dose was
12.41 mg (SD = 6.25). The total annual cost of the anti-
coagulant treatment was €16,546.47, with an average
annual per-patient cost of €17.53 (SD = 9.01). No statisti-
cally significant differences were observed based on gender
(p = 0.081). However, the cost of INR monitoring decreased
in conjunction with increasing patient age (p = 0.00). The
total cost of INR monitoring was €43,751.36, with an
annual per-patient cost of €46.35 (SD = 14.51). No sta-
tistically significant differences were observed based on
gender (p = 0.592) or age (p = 0.995). The total annual
cost of medical visits were estimated at €1,169,492 for
scenario 1, €438,352 for scenario 2, €281,530 for scenario
3, and €278,282 for scenario 4. The mean cost per patient
varied from €1,238.87 (SD = 370.31) in the first scenario to
€290.55 (SD = 87) in the fourth scenario. No gender-based
differences were detected (p = 0.988, p = 0.340, p = 0.955,
and p = 0.990 respectively). Throughout the study period,
nine patients were hospitalized from complications linked
Table 1 Breakdown of patients included in the study
Male Female Overall
Average % SD Average % SD Average % SD
Population N = 581 N = 676 N = 1,257
Age 76.55 9.47 80.01 8.48 78.41 9.11
Age groups
27–74 years 33.22 19.82 26.01
75–80 years 29.78 26.92 28.24
81–84 years 17.90 24.11 21.20
85–99 years 19.10 29.14 24.50
Visits* 13.93 6.58 14.22 6.51 14.08 6.54
Percentage of visits with incident* 19.11 18.93 19.35 18.53 19.24 18.71
INR 2.50 0.40 2.53 0.36 2.52 0.38
Average weekly dose of VKA (mg) 12.93 6.46 11.99 5.96 12.43 6.21
Patients participating in the study for over 5 months N = 435 N = 509 N = 944
Age 76.37 9.27 79.41 8.32 78.01 8.90
Age groups
27–74 years 34.94 22.40 28.18
75–80 years 29.43 28.49 28.92
81–84 years 19.31 22.59 21.08
85–99 years 16.32 26.52 21.82
Visits* 16.59 5.03 16.78 4.98 16.69 5.00
Percentage of visits with incident* 15.88 13.71 17.17 14.24 16.58 14.01
INR 2.50 0.25 2.53 0.25 2.52 0.25
Average weekly dose of VKA (mg) 12.83 6.55 12.05 5.96 12.41 6.25
Note: Stars denote statistically significant differences between the sample and the population at 95% confidence.
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over 65 years of age, five were admitted to hospital follow-
ing a thrombotic episode, and four following a hemorrhage.
The total cost of hospital admissions for these nine patients
was €32,880, with an average per-patient cost of €3,653.33.
The cost of rescue medication was €3,439.04, with a mean
annual cost per patient of €3.64 (SD: 5.53).
To compare each cost item, examine the example of





















Figure 1 Average visits by therapeutic range. Sample: Total visits (17,70represents 0.93% of the total cost, OAT 4.46%, related
admission 8.86%, INR control 11.80%, and medical visits
73.95%. It is clear that across all scenarios the item
representing the largest proportion of the total is that
of hospital visits: 73.95% in scenario 4 , 74.45% in sce-
nario 3, 81.94% in scenario 2, and 92.37% in scenario 1
(see Figure 2).
The Rosendaal method [19] revealed that the longer






Table 2 Unit costs used in the study
Health-care resource Scenario 1 Scenario 2 Scenario 3 Scenario 4
First-hospital visit a,c €124 €124 €124 €17.41
Second and subsequent hospital visits a,c €74 With incident: €74 €17.41 €17.41
Without incident: €17.41
Anticoagulant treatment (VKA)b €0.098/mg
Rescue medicationb LMWH €3.121/dose
Vitamin K: €0.376
INR monitoringc €2.73
DRG hospital admissionc Thrombosis: €5,418
Hemorrhage: €3,736
aSource: regional health service price list (reference [22]).
bSource: Reference [21].
cSource: hospital cost accounting.
LMWH low molecular weight heparin.
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under scenario 4, the patients in Group 2 incurred an
average per-patient cost of €570.29. This sum decreased
to €421 in Group 3 and €340.92 in Group 4. Thus, the
difference in cost between Group 2 and Group 4 is
40.22% under scenario 4 and 52.74% under scenario 1.
Table 4 lists the total average costs and their respective
per-patient and per-year cost items for two groups of
scenario 1 patients: those with TTR under 50% and
those whose TTR was equal to or greater than 50%. The
mean costs for patients whose TTR was under 50% was
€553, while those patients whose TTR was 50% or over
was €376. This represents a difference of €176, or over
44% of the average total cost. The three cost components
underlying this difference are medical visits, hospital
admissions and concomitant medication. These three cost
items account for €160 of the €176 difference seen
between the two groups. When analyzing the cost dif-





















Concomitan medication Related Admissi
Figure 2 Percentage breakdown of overall costs including visits and cof the overall cost, the hospital admissions and the costs
of concomitant medication for patients with TTR below
50% amount to 218.68% of the average cost of hospital
admissions and 226.21% of the average cost of concomi-
tant medication. Text for this sub-section.
Discussion
The characteristics of the patients included in this study
differ slightly from those of the AF patients included
in the PREV-ICTUS study, where there was a mean
age of 75.0 ± 7 and 49.5% were female. Moreover, in
the PREV-ICTUS study only 33% of the AF patients
were receiving OAT [23]. The CARDIOTENS 1999 study
was broader and included AF patients with a mean age of
68.4 ± 10.3 years, 55.9% female participants, and only 28%
receiving OAT [24]. The sampling differences between
the current study and previous studies (particularly the
proportion of females) may be because this study only
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ost sub-groupings. Source: Compiled by the authors (n = 944).
Table 3 Average per-patient cost based on time within the TR (in 2010 Euros)
Scenario 1 Scenario 2 Scenario 3 Scenario 4
Group 1: Less than 25% of time in TR 694.04 382.77 198.84 198.84
Group 2: 25% − 50% of time in TR 1,771.97 911.32 591.08 570.29
Group 3: 50% − 75% of time in TR 1,478.72 633.78 429.31 421.00
Group 4: Over 75% of time in TR 1,160.09 453.92 345.88 340.92
Total 1,341.22 566.70 400.58 392.90
Source: Compiled by the authors. Baseline: Patients included in the sample for a minimum of five months and one day (n = 944).
Non-standard format.
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out in patients with NVAF receiving VKA treatment reveals
that our population is very similar to those of other studies,
as can be seen in a recent work which used a similar popu-
lation and was made up of 56% women and had an average
age of 73 ± 8 years [25]. A study covering several countries,
including Spain, examined patients with NVAF who were
undergoing VKA treatment where the average age of the
patients was 71.6 years and 56% were male [26].
The average annual number of hospital visits made by
the subjects in the study was 14.08 ± 6.54. This figure
was slightly higher than that of other studies carried out
in Spain to date. One study found the average number
of visits to be 12.1 [27], although it was conducted over
a period of ten years in a rural area. A further study,
undertaken in 2003 and included 20,347 patients receiving
VKA treatment monitored by four anticoagulation units
within large hospitals in Spain, found that the average
annual number of visits per patient was 10.42 [17]. Of
the four centers, the one that received the lowest number
of visits recorded an average of 8.21 visits/person/year,
while the one with the highest number of visits recorded
an average of 15.70. Hence, the figures recorded in our
study can be considered representative of clinical practice
in Spain.
The admission rates included in our work (admission
from hemorrhage at 0.31/100 patients/year, and from
pulmonary embolism at 0.39/100 patients/year) are near
average, compared to the results of the aforementioned
study carried out in four large hospitals that reported
admissions from hemorrhage at 0.88/100 patients/year
and from pulmonary embolism at 0.62/100 patients/year
[17]. In the ten-year follow-up study performed in aTable 4 Average cost according to TTR, type of cost (in Euros
Total Treatment INR control
TTR < 49 553.01 20.94 58.13
TTR ≥50 376.85 17.19 45.17
Total 392.90 17.53 46.35
Difference (Dif) 176.16 3.75 12.96
% difference relative to TC 44.84% 21.39% 27.96%
Source: Compiled by the authors. Baseline: Patients included in the sample for a micohort of rural patients, the rates were 1.24/100 patients/
year for hemorrhage and 0.21/100 patients/year for
thrombosis [27].
One study performed in four large Spanish National
Health Service hospitals [17] found higher costs per treat-
ment higher than ours, the difference solely because of
variations in dose, as the price of acenocoumarol is the
same in both cases, €0.03/mg. INR monitoring costs
include medical supplies, logged expenses, and medical
personnel. Our results can be compared with this study
by subtracting the cost of medical staff, which can be
analyzed separately. Our study includes the clinical visits
costs needed for repeated INR monitoring when the
associated values are over 4.5. This can explain why all
visits yielding results above 4.5 reflect two INR moni-
toring sessions rather than one.
Our methodology and the data obtained, allow us to
accurately estimate the actual cost associated with such
patients for the Spanish National Health System. To
our knowledge, this is the first study of its kind to be
published.
Conclusions
The study results demonstrate that patients receiving
VKA treatment require exhaustive follow-up, thus making
anticoagulant therapy a costly intervention. The need for
dose adjustments are brought on by numerous external
but nonetheless common factors, such as changes in
diet, visits to the dentist, or vacation periods. Thus, the
National Health Service is required to provide specific
monitoring and dosage control services in addition to
personalized clinical observation, thereby increasing the
cost of the treatment. Some studies support the creation), and percentages






nimum of five months and one day (n = 944).
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and proper monitoring of anticoagulant therapy. With
the gradual introduction of new drugs, new approaches
will arise in the clinical oversight of this pharmacological
treatment. Our results provide updated and more accurate
data than previously available. Our results provide in-
formation that is relevant to decision-making and that
might prove necessary for future cost-effectiveness studies
comparing current oral anticoagulation drugs with newly
developed drugs. Up to date, close observation of thera-
peutic ranges by specialist services represents the best
way to contain the health care costs associated with
treating NVAF patients receiving VKA treatment.
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